Pharnext — Report Publication Announcement 2017

Sep 13, 2017

Pharnext to Present at 7 th Annual CEC Capital Summit

Paris, France, 5:45pm, September 13, 2017 (CEST) – Pharnext SA (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the 7 th Annual CEC Capital Summit.

The presentation will take place as follows:

• Date: Wednesday, September 20th, 2017
• Time: 2:50 pm PDT (11:50 pm CEST)
• Venue: Montage Beverly Hills in Beverly Hills, California

If you are interested in meeting the Pharnext management team during this event, please send an email to Matthew Shinseki at matthew@sternir.com.

About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287). For more information, visit www.pharnext.com

CONTACTS:

Pharnext Xavier Paoli Chief Commercial Officer contact@pharnext.com +33 (0)1 41 09 22 30

Investor Relations (Europe) MC Services AG Anne Hennecke anne.hennecke@mc-services.eu +49 211 529252 22

Media Relations (Europe) ALIZE RP Caroline Carmagnol Margaux Pronost pharnext@alizerp.com +33 (0)1 44 54 36 64

Investor Relations (U.S.) Stern Investor Relations, Inc. Matthew Shinseki matthew@sternir.com +1 212-362-1200

Media Relations (U.S.) Russo Partners Tony Russo Scott Santiamo tony.russo@russopartnersllc.com scott.santiamo@russopartnersllc.com +1 212-845-4251 +1 718-344-5843

Financial Communication (France) New CAP Emmanuel Huynh pharnext@newcap.eu +33 (0)1 44 71 20 40